Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.
You may also be interested in...
US FDA’s revised draft guidance spelling out its policy on 'refuse-to-file' decisions differs little in substance compared to predecessor issued in 1993. But difference in style is telling sign of the times.
Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.
Generic applications continue to be tripped up by failing to adhere to other well-known standards such as paying user fees, US agency says.